Measuring the Impact of Taking Care in the Context of an Innovative System for Keeping Dependent Elderly People in Their Homes
NCT ID: NCT03976661
Last Updated: 2023-01-12
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
86 participants
OBSERVATIONAL
2019-04-29
2024-04-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Feasibility Assessment of Implementing a Care System to PREVENT Iatrogenic Dependency (ID)
NCT06173154
An In-home Respite Care Program to Support Informal Caregivers of People With Dementia
NCT02630446
Evaluation of Covid-19 Vaccination in Elderly Subjects in Retirement Home (EHPAD) and Long-term Care Units (USLD) in Ile-de-France
NCT04900376
Person Centered Nursing Homes: Impact Assessment Of Centered Person Care In Nursing Homes
NCT03200145
Measuring the Impact of Care in the Cognitive Behavioural Unit
NCT03989245
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
About population :
For quantitative component: the investigators have two arms:
* Diapason 92 arm: will be constitued by older patients with loss of autonomy, living at home and benefiting from Diapason 92 device
* Control arm: will be constituted by people residing at the EHPAD (retirement home)
For qualitative component: Study will cover 5 different populations since it concerns both:- - Diapason 92 professionals who work directly with users
* Daipason 92 Supervisory staff
* Diapason 92 professional partners, including referring physicians.
* The users
* Non-professional helpers of users
Conduct of study:
\- About quantitative component:
After verification of eligibility criteria adapted to each centre and once the non-opposition has been collected and subjects have been included, the following data will be collected at M0, M3, M6 and M12:
* For patients : Start date of care by Diapason 92 or EHPAD, Quality of Life score, benefit evaluation, Socio-educational level, evaluation of disruptive behaviour disorders, economic indicators, somatic comorbidities, collection of psychiatric follow-up if available, independence, nutritional status, factors(s) that motivated care, cognitive assessment, balance assessment, depression screening, ergonomic assessment (only for Diapason 92
* Family caregiver: 3 measures will be collected: Measuring the burden by Zarit scale, self-assessment of his quality of life and psychological condition
* About quality component:
A socio-demographic heel will be collected for each participant interviewed who has given no objection to participating in the study. His agreement on the recording of his voice will also collected.
For all participants, following data will be collected: Age, sex, occupation, date and duration of the interview, relationship with the Diapason 92 user (for family caregivers) and the recovery of socio-demographic data of the case report form (for users)
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
OTHER
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
DIAPASON 92 arm
Arm will be constitued by older patients with loss of autonomy, living at home benefiting from the device DIAPASON 92 (Innovative support system for elderly people in their homes)
No interventions assigned to this group
Control arm
Arm will be constituted by people residing at the EHPAD (retirement home)
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* (Group iso-resources) GIR ≤ 4
* Beneficiary of treatment by Diapason 92 or resident at EHPAD Aulagnier for more than 6 months.
* Not exhibiting severe disruptive behaviour disorders (on NPI-ES all FXG 12 and resonance 4 scores).
* Affiliate or entitled to a sickness insurance scheme
* Patient or legal representative expressed no objection
* Exercise within Diapason 92 device or be identified as assisting a Diapason 92 user or be a professional partner of Diapason 92 device
* Have expressed no objection to participating in the study.
Exclusion Criteria
* GIR ˃ 4
* Not affiliated or entitled to a sickness insurance scheme
* Patient or legal representative did not express no objection
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gérond'if
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Olivier Phd Hanon
Role: PRINCIPAL_INVESTIGATOR
Geriatric department, Broca hospital (Paris)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Geriatric department , Broca Hospital
Paris, Île-de-France Region, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-A03183-52
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.